An Alternative Intermittent Eltrombopag Dosing Protocol for Treatment of Chronic Immune Thrombocytopenia

British Journal of Clinical Pharmacology - United Kingdom
doi 10.1111/bcp.13717
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Wiley

Related search

Eltrombopag-Based Combination Treatment for Immune Thrombocytopenia

Therapeutic Advances in Hematology
Hematology
2018English

Tolerability and Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia

Clinical and Applied Thrombosis/Hemostasis
MedicineHematology
2016English

Recurrent Coronary Thrombus in a Patient With Chronic Immune Thrombocytopenia With Treatment Using Eltrombopag

Case Reports in Cardiology
Cardiovascular MedicineCardiology
2019English

Eltrombopag: An Update on the Novel, Non-Peptide Thrombopoietin Receptor Agonist for the Treatment of Immune Thrombocytopenia

Annals of Hematology
MedicineHematology
2010English

Thrombopoietin Level Predicts Response to Treatment With Eltrombopag and Romiplostim in Immune Thrombocytopenia

American Journal of Hematology
Hematology
2018English

Eltrombopag for Treatment of Thrombocytopenia After Allogeneic Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation
TransplantationHematology
2016English

Eltrombopag, a Thrombopoietin- Receptor Agonist in the Treatment of Adult Chronic Immune Thrombocytopenia: A Review of the Efficacy and Safety Profile

Therapeutic Advances in Hematology
Hematology
2012English

Therapy Induced Iron Deficiency in Children Treated With Eltrombopag for Immune Thrombocytopenia

American Journal of Hematology
Hematology
2017English

Relative Potency of the Thrombopoietin Receptor Agonists Eltrombopag, Avatrombopag and Romiplostim in a Patient With Chronic Immune Thrombocytopenia

British Journal of Haematology
Hematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy